SDC 1: The Proportion of Subjects With OPA Levels Greater Than or Equal to the LLOQ^a (Postvaccination)

		% (95% CI	b)					
Age Group	$\mathbf{n}^{\mathbf{c}}$	Serotype						
PCV7 serotypes		4	6B	9V	14	18C	19F	23F
Younger ^d	175–181	100	100	100	100	100	98.9	100
		(98.0-100)	(97.9-100)	(98.0-100)	(97.9-100)	(97.9-100)	(96.0-99.9)	(97.9-100)
Older ^e	182-188	100	100	100	100	100	100	100
		(98.1-100)	(98.0-100)	(98.0-100)	(98.0-100)	(98.0-100)	(98.0-100)	(98.0-100)
6 additional serotypes		1	3	5	6A	7 F	19A	
Younger ^d	175–180	97.8	99.4	98.9	100	100	100	
		(94.4–99.4)	(96.9-100)	(96.0-99.9)	(97.9-100)	(97.9-100)	(98.0-100)	
Older ^e	173–187	98.9	99.4	94.5	100	100	100	
		(96.2–99.9)	(97.0–100)	(90.2–97.3)	(98.0–100)	(98.0–100)	(98.0–100)	

^aLLOQ in titers for each serotype was set as follows: serotype 1, 18; serotype 3, 12; serotype 4, 21; serotype 5, 29; serotype 6A, 37; serotype 6B, 43; serotype 7F, 210; serotype 9V, 345; serotype 14, 35; serotype 18C, 31; serotype 19A, 18; serotype 19F, 48; and serotype 23F, 13.

^bExact 2-sided CIs based on the observed proportion of subjects.

^cNumber of subjects with an antibody titer who meet the comparison level for the given serotype.

^d≥5–<10 years of age.

 $^{^{}e}\geq$ 10–<18 years of age.